R. Miller1, A. Malfait2, J. Block3
2017 Vol.35, N°5 ,Suppl.107 - PI 0085, PF 0087
Pain in osteoarthritis
Free to view (click on article PDF icon to read the article)
Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemab close to completing Phase 3 trials in preparation for an application for approval for clinical use.
PMID: 28967370 [PubMed]
Received: 16/09/2017 - Accepted : 16/09/2017 - In Press: 28/09/2017 - Published: 29/09/2017